Latest Herceptin Stories
Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor's vulnerability to treatment.
SAN DIEGO, March 11, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc.
For women with aggressive early-stage breast cancer (HER2-positive disease), trastuzumab (Herceptin) given for one year after chemotherapy proved to put the women at significantly less risk of the cancer returning.
Results for testing breast tumors for HER2 proteins and genes is most often straightforward when one piece of tumor (a single tumor block) is analyzed.
SAN DIEGO, Dec. 7, 2010 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc.
INCLINE VILLAGE, Nev., Dec. 1, 2010 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
Red-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein.
SAN DIEGO, Nov. 5, 2010 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc.
A new disposable device based on advances in microfluidics may help identify advanced breast cancer patients who are candidates for therapy with the drug trastuzumab (Herceptin).
INCLINE VILLAGE, Nev., Sept. 1 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.